Clinical Study on Long-Term Overall Survival of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chinese Medicine and Western Medicine

被引:0
|
作者
陈衍智 [1 ]
冯小兵 [1 ]
李占东 [1 ]
郑文献 [1 ]
孙红 [1 ]
李萍萍 [1 ]
机构
[1] Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Department of Integrated Traditional Chinese and Western Medicine,Peking University Cancer Hospital & Institute
关键词
non-small cell lung cancer; long-term overall survival; prognosis; Chinese medicine;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
Objective:To investigate the prognostic influence on long-term overall survival(OS) from treatment with Chinese medicine(CM) and chemotherapy or targeted therapy in advanced non-small-cell lung cancer(NSCLC) patients.Methods:The clinical data of 206 advanced NSCLC patients who were treated with CM and Western medicine in Beijing Cancer Hospital from April 1999 to July 2013 were retrospectively analyzed.Long-term survivors were defined as OS > 3 years after treatment with CM and chemotherapy.Twenty-eight patients had OS > 3 years,178 had OS < 3 years,and all clinical data were statistically analyzed with the Cox model.Variables were gender,age,smoking status,performance status(PS) score,pathological type,clinical stage,first-line chemotherapy,targeted therapy,and use of CM.Univariate survival analysis was performed using the Kaplan-Meier method and log-rank sequential inspection.Multivariate survival analysis was used to analyze the meaningful factors of univariate survival analysis with the Cox model.Results:The survival rate of patients with OS > 3 years was 13.6%(28/206).Cox multivariate regression analysis showed that PS score,clinical stage,disease control rate to first-line chemotherapy,and use of CM were independent factors of longterm OS(all P<0.05).However,gender,age,smoking,and use of epidermal growth factor receptor tyrosinekinase inhibitor were not significant(P>0.05).Conclusion:PS score,clinical stage,disease control rate to firstline chemotherapy,and use of CM are probably independent prognostic factors for long-term OS in patients with advanced NSCLC.
引用
收藏
页码:179 / 183
页数:5
相关论文
共 50 条
  • [21] Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy
    Xu, Zhen Ye
    Jin, Chang Juan
    Zhou, Cai Cun
    Wang, Zhong Qi
    Zhou, Wei Dong
    Deng, Hai Bin
    Zhang, Ming
    Su, Wan
    Cai, Xiao Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (07) : 1117 - 1122
  • [22] Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy
    Zhen Ye Xu
    Chang Juan Jin
    Cai Cun Zhou
    Zhong Qi Wang
    Wei Dong Zhou
    Hai Bin Deng
    Ming Zhang
    Wan Su
    Xiao Yue Cai
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1117 - 1122
  • [23] Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
    Cheema, P. K.
    Burkes, R. L.
    CURRENT ONCOLOGY, 2013, 20 (02) : E150 - E160
  • [24] Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery
    Flannery, Todd W.
    Suntharalingam, Mohan
    Regine, William F.
    Chin, Lawrence S.
    Krasna, Mark J.
    Shehata, Michael K.
    Edelman, Martin J.
    Kremer, Marnie
    Patchell, Roy A.
    Kwok, Young
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : 19 - 23
  • [25] IDENTIFICATION AND CHARACTERIZATION OF LONG TERM SURVIVAL POPULATION IN NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES
    Luaces, P.
    Sanchez, L.
    Viada, C.
    Rodriguez, P. C.
    Alvarez, M.
    Fonte, C.
    Muchene, L.
    Shkedy, S.
    Lage, A.
    VALUE IN HEALTH, 2015, 18 (03) : A193 - A193
  • [26] Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
    von Pawel, J.
    Bordoni, R.
    Satouchi, M.
    Fehrenbacher, L.
    Cobo, M.
    Han, J. Y.
    Hida, T.
    Moro-Sibilot, D.
    Conkling, P.
    Gandara, D. R.
    Rittmeyer, A.
    Gandhi, M.
    Yu, W.
    Matheny, C.
    Patel, H.
    Sandler, A.
    Ballinger, M.
    Kowanetz, M.
    Park, K.
    EUROPEAN JOURNAL OF CANCER, 2019, 107 : 124 - 132
  • [27] Effect of integrated Chinese medical treatment on the survival time of patients with advanced non-small-cell lung cancer: a clinical study
    刘苓霜
    ChinaMedicalAbstracts(InternalMedicine), 2014, 31 (03) : 135 - 135
  • [28] Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
    Bar, Jair
    Urban, Damien
    Amit, Uri
    Appel, Sarit
    Onn, Amir
    Margalit, Ofer
    Beller, Tamar
    Kuznetsov, Teodor
    Lawrence, Yaacov
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [29] Clinical factors predictive of long-term survival in advanced non-small cell lung cancer
    Van Damme, V.
    Govaerts, E.
    Nackaerts, K.
    Dooms, C.
    Wauters, I.
    Vansteenkiste, J.
    LUNG CANCER, 2013, 79 (01) : 73 - 76
  • [30] Personalized medicine for non-small-cell lung cancer
    Mok, Tony S.
    Zhou, Qing
    Leung, Linda
    Loong, Herbert H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1601 - 1611